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Abstract
Background
While a number of predictors for Ebola mortality have been identified, less is known about
post-viral symptoms. The identification of acute-illness predictors for post-viral symptoms
could allow the selection of patients for more active follow up in the future, and those in
whom early interventions may be beneficial in the long term. Studying predictors of both
mortality and post-viral symptoms within a single cohort of patients could also further our
understanding of the pathophysiology of survivor sequelae.
Methods/Principal findings
We performed a historical cohort study using data collected as part of routine clinical care
from an Ebola Treatment Centre (ETC) in Kerry Town, Sierra Leone, in order to identify pre-
dictors of mortality and of post-viral symptoms. Variables included as potential predictors
were sex, age, date of admission, first recorded viral load at the ETC and symptoms
(recorded upon presentation at the ETC). Multivariable logistic regression was used to iden-
tify predictors. Of 263 Ebola-confirmed patients admitted between November 2014 and
March 2015, 151 (57%) survived to ETC discharge. Viral load was the strongest predictor of
mortality (adjusted OR comparing high with low viral load: 84.97, 95% CI 30.87–345.94).
We did not find evidence that a high viral load predicted post-viral symptoms (ocular: 1.17,
95% CI 0.35–3.97; musculoskeletal: 1.07, 95% CI 0.28–4.08). Ocular post-viral symptoms
were more common in females (2.31, 95% CI 0.98–5.43) and in those who had experienced
hiccups during the acute phase (4.73, 95% CI 0.90–24.73).
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Conclusions/Significance
These findings may add epidemiological support to the hypothesis that post-viral symptoms
have an immune-mediated aspect and may not only be a consequence of high viral load
and disease severity.
Introduction
The 2013–2015 Zaire Ebolavirus (EBOV) epidemic in West Africa infected more than 28 000
people, with over 50% of cases occurring within Sierra Leone[1]. While the case fatality from
Ebola Virus Disease (EVD) has been estimated to be as high as 80% based on previous smaller
outbreaks[2], the WHO reported an overall case fatality of around 65% in the West African
outbreak[3]. Estimates of case fatality from individual Ebola treatment centres (ETC) ranged
from 31% to 70%[3,4].
Descriptive analysis from treatment centres caring for patients during the West African
outbreak has improved our understanding of common presenting features of EVD, which are
now characterised into three stages; stage 1: non-specific symptoms, stage 2: gastrointestinal
symptoms, and stage 3: neurological symptoms and organ failure[5]. Signs and symptoms
associated with severe (advanced) EVD include: hiccups, confusion, depressed consciousness,
seizures, difficulty breathing, and bleeding[6]. Follow-up of survivors of the West African epi-
demic, mostly from small cohorts, indicates a high frequency of debilitating post-viral symp-
toms[7–12], as well as considerable psychosocial challenges[13–16]. To date, however, there
has been limited examination of which patient characteristics, and/or presenting symptoms or
signs, are predictors of post-viral symptoms, and whether these are the same as predictors for
mortality during the acute phase of the disease. The identification of acute-illness predictors
for late-onset survival symptoms would allow the identification of patients for more active fol-
low up, and those in whom early interventions may be beneficial in the long term, as well as
furthering our understanding of the pathophysiology of survivor sequelae. Here, we analyse
predictors of both mortality and sequelae within the same large cohort of patients cared for
during acute illness and recovery in a single ETC.
Our primary aim was to identify risk factors for (i) mortality and (ii) ocular and musculo-
skeletal post-viral symptoms within a single EVD-infected cohort. Our secondary aim was to
describe the types and prevalence of post-viral symptoms experienced by survivors, adding to
emerging evidence on EVD sequelae.
Methods
Study design
This was an historical cohort study using de-identified data captured during routine clinical
care of (i) people infected with EBOV and (ii) a subset of these who survived acute disease.
Study participants and setting
The study population consisted of all people admitted to the 80-bed Kerry Town ETC in the
Western Area Rural District, Sierra Leone, between 5 November 2014 and 31 March 2015.
This ETC was operated by Save the Children International in partnership with the United
Kingdom (UK) and Sierra Leonean governments, and the Cuban Medical Brigade.
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The ETC admitted patients with suspected or previously lab-confirmed EBOV, mostly orig-
inating from the nearby Western Area Urban or Western Area Rural districts. Further details
on admission, care and discharge procedures can be found in the Supporting Information and
elsewhere[17,18]. All survivors (i.e. initially EBOV PCR-positive individuals who had three
EVD symptom-free days and two consecutive EBOV PCR-negative tests and were discharged
from the ETC) were invited to attend the survivor clinic which ran from 2 April 2015 until 30
June 2015, whether or not they had any symptoms (see Supporting information for full
details).
Patients who had a documented positive EBOV PCR test from the onsite Public Health
England Laboratory and who were inpatients at the Kerry Town ETC were eligible for this
study and were included in the analysis of risk factors for EVD mortality. Survivors among
these were included in the post-viral symptoms analyses if they attended the survivor clinic at
least once (Fig 1).
Subsets of the cohort of 263 participants included in this study have been included in previ-
ous publications: 150 in a study of survival in the ETC[19]; 112 survivors in a study of persis-
tent viral excretion[20]; all 151 survivors in a study of long term mortality[21] and 123
survivors in a series of studies on household transmission[22–25] (See Supporting information
for further details).
Data collection
We used routinely-collected de-identified clinical data, originally recorded on standardised
clinical record forms at the ETC, supplemented where applicable by case investigation form
data carried by patients referred from other facilities. Diagnosis of EBOV infection was made
using reverse-transcriptase-PCR (RT-PCR) assay performed using the Altona RealStar Filovi-
rus RT-PCR Kit (Altona, Hamburg, Germany), after inactivation and manual RNA extraction,
as previously described[19]. People who arrived at the ETC with case investigation forms from
other facilities indicating they were EBOV PCR-positive were admitted to the ETC and
retested by the onsite Public Health England laboratory.
At the survivor clinic, attendees were initially screened for acute infection as described pre-
viously[20]. Survivor clinic attendees were seen by a clinician who recorded the patients’ self-
reported symptoms experienced in the preceding seven days on a standardised form and also
recorded clinical signs, symptoms, and any clinical diagnoses made during the examination. A
Krio translator was used if necessary. If requested by the attending clinician, blood samples
were taken for haematological and biochemical analysis. Survivors with symptoms and/or a
diagnosis requiring specialist input were referred to hospitals. A psychosocial assessment was
also performed by a trained psychologist at the majority of survivor clinic visits. See Support-
ing Information for further data collection details.
Ethics
The Sierra Leone Ethics and Scientific Review Committee granted ethical approval for this
study. As this study used de-identified clinical data collected for the purposes of routine clini-
cal care only, individual consent was not sought.
Outcomes and risk factors
Mortality analysis. Variables included as potential risk factors were sex, age, date of
admission, viral load on admission (EBOV RT-PCR cycle threshold value was used as a proxy)
and any of the following symptoms or signs recorded upon admission: fever, fatigue/weakness,
vomiting/nausea, diarrhoea, conjunctivitis/red eye, muscle/joint pain, headache, difficulty
Ebola mortality and survival in Sierra Leone 2014-2015
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Fig 1. Flow diagram of individuals included in the analysis of EVD mortality and survival in Kerry Town, Sierra
Leone, 2014–2015. �EBOV-: Admitted to the ETC as a suspect case based upon meeting EVD case definition.
Laboratory test for EBOV performed at laboratory located at Kerry Town ETC and result was negative. Individual
discharged (or referred) and not included in this study. †Died EBOV-: Person recovered from Ebola (i.e. three EVD
symptom-free days and two consecutive EBOV-negative tests) but then died during the ETC discharge procedure.
Classified as “recovered” in the mortality analysis, but not included as a survivor in the survivor analysis as did not
survive to discharge from the ETC.
https://doi.org/10.1371/journal.pone.0209655.g001
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breathing, skin rash, hiccups, unexplained bleeding, or confusion. See S1 Text for further
details on risk factors.
Post-viral symptoms analyses. For the EVD survivor post-viral symptoms analyses, we
used only self-reported post-viral symptom data collected as part of routine clinical care at the
survivor clinic, with symptoms selected from a standardised form following the question,
“have you had any of the following symptoms within the previous seven days”.
For the risk factor analysis, we initially considered the three most prevalent types of post-
viral symptoms reported in the literature as potential outcomes: ocular, musculoskeletal, and
auditory [8–10]. Based on the results of our descriptive analysis of symptoms self-reported by
our cohort we restricted this to any (self-reported) ocular symptom (which included any one
of: ocular pain, photophobia, hyperlacrimation, loss of vision, foreign body sensation in the
eye, red eye) and any (self-reported) musculoskeletal symptom (which included any one of:
joint pain, back pain, muscle pain, movement problems, or jaw pain).
The potential risk factors included were sex, age, and information from the acute phase of
infection: total days admitted to ETC, number of days between ETC discharge and survivor
clinic attendance, viral load from the first test at the ETC, and having any one of the 10 symp-
tom risk factors detailed in the mortality analysis section above upon presentation at the ETC
during the acute-phase of infection.
Statistical analysis
Analysis of risk factors for mortality and post-viral symptoms. Crude odds ratios
(ORs) were calculated for the association between each specific outcome and each potential
risk factor. An initial multivariable logistic regression model was then prepared that included
the RT-PCR threshold value variable split into tertiles (included on an a-priori basis as key risk
factor for all outcomes) and all variables listed in the “Mortality analysis” section above as
potential risk factors[26]. For the mortality analysis, age and date of admission were included
in the model as continuous variables. For the post-viral analyses, age, total days admitted to
ETC, and days since discharge were included in the model as continuous variables. A final
model was then obtained by removing all potential risk factors with p>0.2 from the fully-
adjusted model in a backward-stepwise fashion (see S1 Text).
Missing data and sensitivity analyses. Missing risk factor data were assumed to be miss-
ing at random[27], and were accounted for using multiple imputation by chained equations
(see S1 Text). We performed two RT-PCR sensitivity analyses: (i) one where RT-PCR value
was not included a priori and (ii) one where RT-PCR was included as a continuous variable.
We also repeated the analysis including acute-phase symptom risk factors recorded at any
time during ETC stay (not just upon presentation), and using the lowest recorded RT-PCR
value (equivalent to the highest viral load) during ETC stay (rather than the first recorded).
Results
Participants
Between 5 November 2014 and 27 March 2015, there were 456 total admissions to Kerry
Town ETC, 271/456 (59%) of whom were EBOV PCR-positive. Of these, three had missing
outcome data and five had missing data for all symptoms, leaving 263 people in the predictors
for mortality analysis (Fig 1). 151/263 (57%) of these survived to ETC discharge, 141/151
(93%) attended the survivor clinic at least once, 137/141 (98%) of whom had sufficient symp-
tom data for the post-viral symptoms analyses (Fig 1).
Ebola mortality and survival in Sierra Leone 2014-2015
PLOS ONE | https://doi.org/10.1371/journal.pone.0209655 December 27, 2018 5 / 17
Cohort description
The 263 eligible patients had a median age of 25 years (IQR 14–35) and 148/263 (56%) were
female (Table 1). The most common symptoms recorded upon presentation at the ETC were
fatigue/weakness (213 out of 242 people who had data available for the symptom, 88%) and
fever (212/242, 88%). Vomiting/nausea (160/242, 66%), headache (149/242, 62%), muscle/
joint pain (158/242, 65%), and diarrhoea (150/242, 62%) were also common (Table 1). Unex-
plained bleeding was less common (25/242, 10%), as was skin rash (10/242, 4%). Median
length of stay at the ETC was nine days (IQR 6–14) for those who survived, compared with
three days (IQR 2–5) for those who died.
Mortality
Analysis of risk factors for mortality. RT-PCR cycle threshold (CT) was the strongest
predictor of mortality (Table 1), with those with a low CT value (high EVD viral load) at ETC
admission having 85 times higher odds of death than those with a high threshold value on
admission, after multivariable adjustments. In addition, presenting at the ETC in a confused
state was a strong predictor of mortality (OR 15.93, 95% CI 2.56–98.97). Mortality increased
with age in adults, and was lower in those admitted in December and January than those
admitted in November.
In a post hoc analysis we found that none of the 18 people with a CT value less than 15.9
upon admission survived, while none of the 29 people with a CT value greater than 29.0
died.
Survivors’ post-viral symptoms
Description of survivors and prevalence of post-viral symptoms. Of the 138 people
included in the post-viral symptoms analysis, the median number of days from ETC dis-
charge to first survivor clinic visit was 109 (IQR 91–210) (Table 2). The majority (64%) of
people attended the clinic on two occasions, with the remainder either attending only once
(30%) or three times (6%). (S2 Table). Any ocular symptom (100/137 of people who had any
symptom data recorded, 73%), any musculoskeletal symptom (107/137, 78%) and headache
(63/80, 79%) were the most commonly self-reported problems, with photophobia the most
commonly reported specific ocular symptom (46%) and joint pain the most commonly
reported musculoskeletal symptom (62%). Excess hunger (99/137, 72%), hair loss (61/137,
45%), fever (55/137, 40%), and dry mouth (52/137, 38%) within the previous seven days
were also commonly reported. Hearing loss or tinnitus was reported by 30/137 people
(22%).
Analysis of risk factors for ocular or musculoskeletal post-viral symptoms. Results of
multivariable logistic regression for the ocular and musculoskeletal post-viral outcomes are
shown in Table 3. Age was a predictor of musculoskeletal symptoms (with younger age being
protective). Among signs and symptoms during acute-phase admission, there was a suggestion
that hiccups was associated with a higher risk of ocular symptoms, although confidence inter-
vals spanned the null value. There was weak evidence that female gender predictor ocular
symptoms. We did not find evidence that viral load on admission predicted the occurrence of
either ocular (1.17, 95% CI 0.35–3.97, comparing low to high CT value) or musculoskeletal
(1.07, 95% CI 0.28–4.08) post-viral outcomes in our analysis, although wide confidence inter-
vals meant that we were unable to rule out an increased effect (of up to approximately 4 times
the odds) for both outcomes.
Ebola mortality and survival in Sierra Leone 2014-2015
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Table 1. Predictors for mortality amongst all EBOV-positive people admitted to Kerry Town ETC.
All
n (%)
Recovered
n (%)
Died Crude OR�
(95% CI†)
Multivariable‡
OR (95% CI)
Total§ 263 (100) 152 (58) 111 (42) - -
Gender Male 115 (44) 60 (52) 55 (48) 1 -
Female 148 (56) 92 (62) 56 (38) 0.66 (0.41–1.09) -
Age in years <5 21 (8) 10 (48) 11 (52) 2.82 (1.19–7.00) 2.36 (0.48–11.64)
5–14 48 (18) 35 (73) 13 (27) 0.95 (0.40–2.25) 0.92 (0.27–3.19)
15–24 57 (22) 41 (72) 16 (28) 1 1
25–34 71 (27) 34 (48) 37 (52) 2.79 (1.33–5.86) 3.80 (1.25–11.56)
35–44 34 (13) 16 (47) 18 (53) 2.88 (1.19–7.00) 4.68 (1.27–12.28)
45+ 32 (12) 16 (50) 16 (50) 2.56 (1.04–6.32) 8.82 (2.17–35.87)
Date of Nov 14 42 (16) 14 (33) 28 (67) 1 1
Admission Dec 14 160 (61) 100 (63) 60 (38) 0.30 (0.15–0.61) 0.20 (0.06–0.64)
Jan 15 34 (13) 22 (65) 12 (35) 0.27 (0.11–0.71) 0.18 (0.04–0.75)
Feb/Mar 15 27 (10) 16 (59) 11 (41) 0.34 (0.13–0.93) 0.48 (0.10–2.24)
RT-PCR cycle High 78 (36) 68 (87) 10 (13) 1 1
threshold¶ (n = 214)# Med 68 (32) 44 (65) 24 (35) 3.71 (1.61–8.54) 5.90 (2.05–16.95)
Low 68 (32) 10 (15) 58 (85) 32.85 (12.61–85.60) 84.97 (30.87–345.94)
Fever�� (n = 242) No 30 (12) 16 (53) 14 (47) 1 -
Yes 212 (88) 125 (59) 87 (41) 0.83 (0.39–1.76) -
Fatigue/weakness (n = 242) No 29 (12) 18 (62) 11 (38) 1 -
Yes 213 (88) 123 (58) 90 (42) 1.18 (0.54–2.58) -
Vomiting/nausea (n = 242) No 82 (34) 47 (57) 35 (43) 1 -
Yes 160 (66) 94 (59) 66 (41) 0.93 (0.54–1.60) -
Diarrhoea (n = 242) No 92 (38) 57 (62) 35 (38) 1 -
Yes 150 (62) 84 (56) 66 (44) 1.24 (0.72–2.16) -
Conjunctivitis/red eye (n = 242) No 145 (60) 90 (62) 55 (38) 1 -
Yes 97 (40) 51 (53) 46 (47) 1.46 (0.86–2.49) -
Muscle/joint pain (n = 242) No 84 (35) 47 (56) 37 (44) 1 -
Yes 158 (65) 94 (59) 64 (41) 0.86 (0.51–1.46) -
Headache (n = 242) No 93 (38) 47 (51) 46 (49) 1 1
Yes 149 (62) 94 (63) 55 (37) 0.60 (0.35–1.02) 0.51 (0.23–1.15)
Difficulty breathing (n = 242) No 197 (81) 113 (57) 84 (43) 1 -
Yes 45 (19) 28 (62) 17 (38) 0.81 (0.42–1.57) -
Skin rash (n = 242) No 232 (96) 135 (58) 97 (42) 1 -
Yes 10 (4) 6 (60) 4 (40) 0.93 (0.26–3.32) -
Hiccups (n = 242) No 203 (84) 120 (59) 83 (41) 1 -
Yes 39 (16) 21 (54) 18 (46) 1.29 (0.66–2.53) -
Unexplained bleeding (n = 242) No 217 (90) 130 (60) 87 (40) 1 -
Yes 25 (10) 11 (44) 14 (56) 1.94 (0.85–4.44) -
Confusion (n = 242) No 226 (93) 139 (62) 87 (38) 1 1
Yes 16 (7) 2 (13) 14 (87) 11.29 (2.47–51.54) 15.93 (2.56–98.97)
�: Odds ratio. Multiple imputation (MI) used to account for missing data for all variables with missing data. MI model included all variables in this table and the
outcome status.
†: Confidence interval
‡: An initial multivariable regression model was prepared that included all variables in this table. The final model presented here was obtained by removing variables
from the initial fully-adjusted model in a backwards stepwise fashion, keeping only those variables with p�0.2. Age was included as a continuous variable
(multivariable-adjusted categorical results presented to aid interpretation of results).
§: Total = total number of EBOV-positive people admitted to Kerry Town ETC
¶: First recorded RT-PCR cycle threshold value at ETC (inverse indicator of viral load), categorised into tertiles of the distribution of the variable (Low: <18.6 cycles,
medium: 18.6-<22.5 cycles, high:�22.5 cycles).
#: The figures in parentheses indicate the total number of individuals with any data recorded for that variable. Missing values for any variable with missing data were
imputed using multiple imputation (see note 1). See S4 Table for a comparison of analysing the imputed data versus complete records only
��: All symptoms in first column of this table were recorded by clinical staff on presentation at the Ebola Treatment Centre.
https://doi.org/10.1371/journal.pone.0209655.t001
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Table 2. Demographic information and self-reported symptoms in 138 attendees of the Kerry Town Ebola survi-
vors clinic.
N� n† %
Total 138 138 100
Median age (IQR) years 138 21 (14–30) -
Female 138 78 57
Median days from ETC discharge to first clinic visit (IQR) 138 109 91–120
Referred to specialist clinic‡ 138 68 49
Self reported symptoms at survivor clinic§
Fever 137 55 40
Any ocular symptom¶ 137 100 73
Ocular pain 136 55 40
Photophobia 136 63 46
Hyperlacrimation 136 50 37
Loss of vision 136 38 28
Foreign body sensation in the eye 134 47 35
Red eye 136 43 32
Any musculoskeletal symptom¶ 137 107 78
Joint pain 137 85 62
Back pain 137 59 43
Muscle pain 123 49 40
Movement problems 135 31 23
Jaw pain 137 30 22
Chest pain 137 45 33
Parotid pain 135 24 18
Pain with chewing 137 32 24
Hair loss 137 61 45
Peripheral oedema 137 10 7
Headache# 80 63 79
Memory loss/disorientation 134 31 23
Hearing loss or tinnitus 137 30 22
Excess hunger/voracious appetite 137 99 72
Abnormal/foul taste or change in taste 136 30 22
Dry mouth 137 52 38
Genital problems 135 24 18
Amenorrhea 77 14 18
Testicular pain 60 3 5
Testicular oedema 60 2 3
�: Total number of people with data for the specific variable.
†: Number of people who had the variable in question (e.g. for symptoms, n = number who reported having had the
symptom in the previous 7 days).
‡: Clinic attendee symptoms required referral to specialist clinic based on symptoms they presented with at the
survivor clinic
§: Clinic attendee questioned to see if they had had any of the listed symptoms within the previous 7 days
¶: Post-viral symptom outcomes selected for further analysis. The 6 eye-related symptoms were combined into the
composite outcome “Any ocular symptom” (meaning that a person had at least one of the following symptoms:
ocular pain, photophobia, hyperlacrimation, loss of vision, foreign body sensation in the eye, or red eye) while the 5
musculoskeletal-related symptoms were combined into the composite outcome “Any musculoskeletal symptom”
(meaning that a person had at least one of the following symptoms: joint pain, back pain, muscle pain, movement
problems, jaw pain)
#: Data only available for headache for 80 people due to early version of data collection forms not including headache
as a symptom.
https://doi.org/10.1371/journal.pone.0209655.t002
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Missing data and sensitivity analysis
Our complete-records sensitivity analyses showed minimal differences from the analysis of
our imputed datasets (S3 and S4 Tables). Including RT-PCR CT value as a continuous variable
in our model or not including it had a negligible impact on results. The results of repeating the
analyses using the lowest RT-PCR CT value during ETC admission (rather than the first) and
including the occurrence of symptoms at any time during ETC admission (rather than just on
presentation) are included in the S5 and S6 Tables. For all analyses, results were similar with
the exception of unexplained bleeding and mortality: the presence of bleeding at any time dur-
ing ETC admission was associated with a three-fold increase in the odds of mortality 3.08
(1.06–8.90).
Discussion
In this study, we examined both predictors of mortality and predictors of sequelae from EVD
within the same large cohort of patients cared for in a single ETC during both their acute ill-
ness and their recovery. Exploration of this single patient population may remove confounding
due to systematic differences among treatment centres and cohorts. While high viral load on
admission predicted mortality, it did not predict post-viral symptoms. Results from our post
hoc analysis suggest that there may be CT value thresholds below and above which death or
survival are highly likely (within comparable care settings). People who presented at the ETC
in a confused state had a higher odds of death, as did those who suffered from unexplained
bleeding at any time during ETC stay (as opposed to upon presentation at ETC). Apart from
age (which was a predictor of both mortality and musculoskeletal symptoms), there were no
factors that predicted both mortality and the occurrence of post-viral symptoms. There was a
suggestion that hiccups predicted post-viral ocular symptoms, and weak evidence for an asso-
ciation between ocular symptoms and gender.
Comparison with previous studies
Predictors of mortality. Our finding that a low CT value (i.e. high viral load) on admis-
sion predicts mortality is consistent with other studies of the association[4,19,28–32]. A num-
ber of previous studies have shown older and younger age to predict mortality
[3,15,17,29,30,32]–in our study we found a strong association with older age, but were under-
powered to detect an effect in those under the age of 15 (although notably could not rule out
an association as large as 11.64 in the under 5 year old age group). In common with our study,
groups who recorded bleeding on triage tended not to find an association with mortality
[29,30] while those who recorded bleeding at any time during hospitalisation did find an asso-
ciation[32–34]. This is probably because bleeding indicates severe disease, and people already
bleeding in the community are less likely to survive to present at an ETC. Our finding that
confusion is a strong predictor for mortality is consistent with other studies (30,35). Our find-
ing that people admitted in later months were more likely to survive could reflect earlier detec-
tion of cases in the community (therefore people receive medical care at the ETC earlier in the
course of the disease as time goes on), or improving care generally at the ETC over time. The
result is also consistent with other studies that have suggested this could be survival bias:
patients presenting earlier are likely to be local to the ETC and present early in the course of
the disease, whereas those presenting later are from further away, meaning early deaths occur
in the community or at holding centres, rather than at the ETC [35,36].
In contrast to previous studies[17,33,34,37], we did not find that diarrhoea predicted death.
This discrepancy could be explained by: (i) difference in ages of the cohorts under study (i.e.
children are more susceptible to the effects of diarrhoea)[17], (ii) presentation of only
Ebola mortality and survival in Sierra Leone 2014-2015
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Table 3. EVD acute-phase predictors for ocular or musculoskeletal post-viral symptoms amongst people admitted to the Kerry Town ETC who survived and
attended at least 1 Kerry Town EVD survivor clinic.
N† (%) Any ocular symptom� Any musculoskeletal symptom�
n† (%) Crude OR‡ (95% CI) MV§OR (95% CI) n (%) Crude OR (95% CI) MV OR (95% CI)
Total 137 (100) 100 (73) - - 107 (78) - -
Days admitted¶ (n = 135)#:
median (IQR) 9 (6–14) 9 (6–14) 0.99 (0.93–1.06) - 10 (5–14) 1.06 (0.98–1.15) 1.09 (0.99–1.19)
Days since discharge:
median (IQR) 109 (91–120) 108 (91–121) 1.00 (0.99–1.01) - 110 (86–123) 1.00 (0.99–1.01) -
Female gender 77 (56) 60 (78) 1.76 (0.83–3.77) 2.31 (0.98–5.43) 61 (79) 1.16 (0.51–2.62) -
Age:
<5 9 (7) 6 (67) 1.00 (0.17–5.88) - 4 (44) 0.09 (0.02–0.58) 0.09 (0.01–0.63)
5–14 32 (23) 25 (78) 1.20 (0.42–3.41) - 21 (66) 0.45 (0.16–1.30) 0.29 (0.08–1.04)
15–24 40 (29) 28 (70) 1 - 33 (82) 1 1
25–34 30 (22) 22 (73) 1.14 (0.38–3.40) - 25 (83) 1.35 (0.36–5.02) 0.78 (0.17–3.51)
35–44 15 (11) 10 (67) 0.73 (0.22–2.43) - 13 (87) 1.76 (0.33–9.32) 1.32 (0.22–7.95)
45+ 11 (8) 9 (82) 2.00 (0.38–10.51) - 11 (100) -¶¶ -
RT-PCR�� (n = 110) -
High 44 (40) 33 (75) 1 1 34 (77) 1 1
Med 36 (33) 23 (64) 0.64 (0.25–1,67) 0.68 (0.24–1.89) 27 (75) 0.90 (0.33–2.47) 0.98 (0.28–3.39)
Low 30 (27) 22 (73) 0.92(0.31–2.69) 1.17 (0.35–3.97) 24 (80) 1.24 (0.41–3.75) 1.07 (0.28–4.08)
Fever†† (n = 126) 112 (89) 83 (74) 0.92 (0.24–3.46) - 86 (77) 0.47 (0.10–2.28) -
Fatigue/weakness (n = 126) 109 (87) 83 (76) 1.80 (0.60–5.42) - 84 (77) 0.75 (0.20–2.77) -
Vomit/nausea (n = 126) 83 (66) 60 (72) 0.64 (0.27–1.52) 0.40 (0.15–1.10) 64 (77) 0.88 (0.36–2.14) -
Diarrhoea (n = 126) 75 (60) 54 (72) 0.66 (0.29–1.50) - 61 (81) 1.64 (0.70–3.85) 2.37 (0.86–6.51)
Conjunctivitis/Red eye‡‡ (n = 126) 57 (45) 44 (77) 1.44 (0.65–3.21) - 48 (84) 2.16 (0.90–5.21) 2.44 (0.88–6.75)
Muscle/joint pain (n = 126) 85 (67) 66 (78) 1.86 (0.83–4.16) 2.04 (0.78–5.28) 66 (78) 0.98 (0.40–2.41) -
Headache (n = 126) 85 (67) 63 (74) 1.03 (0.43–2.46) - 64 (75) 0.65 (0.26–1.65) -
Diff breathing (n = 126) 23 (18) 18 (78) 1.40 (0.48–4.09) - 16 (70) 0.58 (0.21–1.60) 0.25 (0.06–0.97)
Skin rash (n = 126) 5 (4) 5 (100) -¶¶ - 5 (100) -¶¶ -
Hiccups (n = 126) 20 (16) 18 (90) 3.59 (0.78–16.45) 4.73 (0.90–24.73) 18 (90) 2.81 (0.60–13.04) 6.25 (0.80–48.89)
Bleeding§§(n = 126) 11 (9) 8 (73) 0.90 (0.22–3.66) - 10 (91) 2.71 (0.33–22.12) -
Confusion‡‡ (n = 126) 1 (1) 1 (100) -¶¶ - 1(100) -¶¶ -
�: Self-reported. See Table 2 for list of symptoms.
†: N(%) = total number of people with potential predictor characteristic or symptom (column %), n(%) = number of people for each potential predictor who had the
outcome (row %)
‡: Odds Ratio (95% confidence interval). Multiple imputation (MI) used to account for missing data. MI model included all variables in this table except skin rash,
confusion and the outcome.
§: MV = Multivariable regression model. Model included all variables with results in this column (with variables selected for inclusion from an initial model adjusted for
all variables except skin rash and confusion, using a backward stepwise approach, removing variables with p>0.2). Days admitted, age and time since discharge were
included as continuous variables (categorical results presented to aid interpretation of results).
¶: Days admitted = length of stay at ETC receiving clinical care during Ebola acute-phase of infection.
#: The figures in parentheses indicate the total number of individuals for whom this data was available from acute phase (ETC) records. Missing values were imputed
using multiple imputation (see note 1). See S4 Table for a comparison of analysing the imputed data versus complete records only.
��: First recorded EBOV RT-PCR cycle threshold at ETC (inverse indicator of viral load), categorised into tertiles of the distribution of the variable (Low: <18.6 cycles,
medium: 18.6-<22.5 cycles, high:�22.5 cycles).
††: All symptoms column 1: recorded by clinical staff on presentation at the Ebola Treatment Centre.
‡‡: Data only captured on presentation (not available for capture on standardised forms as an inpatient).
§§: Unexplained bleeding.
¶¶: Could not be estimated due to low numbers.
https://doi.org/10.1371/journal.pone.0209655.t003
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unadjusted results in other studies[34], or (iii) potential differences in patient management in
other settings compared to Kerry Town where use of IV fluids was part of standard care.
Symptoms in survivors and their predictors. In common with our study, a number of
studies found that musculoskeletal symptoms were amongst the most frequent problems expe-
rienced by survivors [8–10,14]. Ocular symptoms in survivors are also commonly reported
elsewhere[8–10,14].
In common with several previous studies[9,10], we did not observe an association between
viral load and either ocular or musculoskeletal sequelae. One study from Port Loko, Sierra
Leone, has reported a dose-response association between viral load and ocular outcomes[8],
though in that study ocular outcomes were ascertained during ETC admission as well as post-
discharge, and included assessment of visual acuity and slit-lamp examinations.
Two previous studies [8,10] found that women had an increased risk of ocular symptoms,
though relative risks were imprecise. To our knowledge there are no other studies that have
studied hiccups as a potential predictor of post-viral symptoms.
Implications and further work
One hypothesis for the underlying cause of EVD post-viral symptoms is persistence of the
virus within immune privileged sites[38], which is more likely in patients with high viral load
and severe, prolonged disease[39,40]. An alternative (but not necessarily exclusive) theory is
based upon the observation that EBOV infection results in substantial immune activation[40],
and that it is this that causes the observed post-viral symptoms[8].
Our findings are more consistent with the latter theory: we found that viral load on admis-
sion was not predictive of post-viral symptoms. The suggestion of greater risk of ocular
sequelae among women is in line with gender imbalances in a number of immuno-inflamma-
tory conditions (including chronic fatigue syndrome/myalgic encephalopathy, rheumatoid
arthritis, and multiple sclerosis)[41,42], and emerging understanding of the impact of sex on
immune function during viral infection[43].
The similarity of some post-EVD sequelae to the symptoms of chronic fatigue syndrome
has been noted previously, and suggestions have been made that Ebola survivors could be
managed by approaches similar to those used for chronic fatigue syndrome or alternatively
treated prophylactically with disease-modifying anti-rheumatic drugs (e.g. sulfasazine)[7,44–
46]. Furthermore, insatiable hunger, weight loss, palpitations and fever are symptoms of
hyperthyroidism, while hair loss, memory loss, low mood, arthralgia and amenorrhoea are
symptoms of hypothyroidism (with eye problems symptomatic of both conditions). Since ani-
mal models of EBOV infection have demonstrated thyroiditis, further evaluation of thyroid
function in survivors is warranted[47].
Our finding of a potential role of hiccups in predicting post-viral ocular symptoms is some-
what difficult to explain. Hiccups can be caused by acute renal failure, central nervous system
irritation and paralytic ileus, all of which have been described in acute EVD and which certainly
could be associated with a high level of systemic inflammation[19,48,49]. The observation that
higher viral load on admission was not associated with survivor symptoms but hiccups were
may support the hypothesis that survivor symptoms are an immune-mediated phenomenon
rather than a consequence of viral persistence. We should also note that the confidence inter-
vals were wide and multiple comparisons were made, so this could be a chance finding.
Limitations
Our study has a number of important limitations. Wide confidence intervals for many of the
associations we explored may be due to low power (i.e. cohort size), and should thus be
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interpreted with caution. All of the information for patients with EVD was captured under
extreme conditions in an emergency setting and was retrospectively obtained from routinely
collected records, meaning that data quality may be an issue.
We chose to base our main analysis on ETC risk factor data obtained upon presentation
at ETC in order to minimise unobserved confounding related to factors such as the impact
of treatment over time. This does mean that our analysis is susceptible to a degree of mea-
surement error (e.g. some people not displaying a specific symptom at presentation may go
on to exhibit it). However, apart from the bleeding finding discussed above, our sensitivity
analysis using data obtained anytime during ETC admission did not lead to alternative
conclusions.
We did not seek to characterise observed sequelae by analysing laboratory test results, as
these were not available for the majority of our cohort. It is difficult to be certain that all post-
viral outcomes were EVD, as we lacked a local healthy population control group. While the
prevalences found were similar to other studies of EVD survivors, those also lacked control
groups. Eliciting history of symptoms during survivor clinics may likewise suffer from
response biases related to poor communication of biomedical concepts or perceived incentives
to over- or under-report. Our estimates were similar to other studies that did include results
from diagnostics, however.
It was not possible in our study to assess the extent to which survivor symptoms improved
or worsened over time, and the limited number of survivor follow-up visits and relatively short
follow-up time mean that we may have missed some survivor outcomes. We also had to make
a pragmatic decision about what type of survivor symptom outcomes to study, could not study
all available recorded post-viral symptoms as outcomes (for which there may be different pre-
dictors), and did not have access to results of specialised consultations for patients who were
referred elsewhere from the survivor clinic (meaning we would not know if a patient went on
to be diagnosed with severe sequelae such as e.g. severe neurological complications, depres-
sion, arthritis, or uveitis). Furthermore, in this study we have focused only on the clinical
symptoms of survivors. We acknowledge that the psychosocial aspects of recovery are equally
important to the well-being of those surviving the disease.
Finally, our patient population may not be representative of the entire EVD epidemic,
though this is counterbalanced by being able to follow a single cohort from admission at ETC
until reporting of post-viral symptoms.
Conclusions
In this study we were able to examine risk factors for both mortality and sequelae from EVD
in a single large cohort. Although viral load in the acute phase of EVD (upon ETC admission)
predicted mortality, surprisingly we did not find it to be an important predictor of ocular or
musculoskeletal symptoms in survivors. In contrast, female gender was predictive of ocular
sequelae, and there was weak evidence that hiccups was also predictive These findings may
add epidemiological support to the hypothesis that post-viral symptoms have an immune-
mediated aspect and may not only be a consequence of high viral load and disease severity.
As evidence accumulates from different study sites, we believe that a systematic review and
meta-analysis of post-viral symptoms and their predictors would be worthwhile, as would
pooled analysis: the latter, in particular, would resolve possible issues with low study power.
Such summary analyses, however, would benefit from standardised case definitions of health
problems being studied and time criteria, e.g. for what constitutes the acute and post-viral
phases. It will also be essential to include a population control group as many of the symptoms
may be common in the general population as well.
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